Impact of conjugate Haemophilus influenzae type b (Hib) vaccine introduction in South Africa.

811Bulletin of the World Health Organization | October 2006, 84 (10) Objective To analyse trends in reported invasive Haemophilus influenzae disease in South Africa within the first five years of introduction of conjugate Haemophilus influenzae type b (Hib) vaccine in the routine child immunization schedule. Methods We used national laboratory-based surveillance data to identify cases of invasive H. influenzae disease between July 1999 and June 2004, and submitted isolates for serotyping and antimicrobial susceptibility testing. Findings The absolute number of Hib cases (reported to the national surveillance system) among children below one year of age decreased by 65%, from 55 cases in 1999–2000 to 19 cases in 2003–04. Enhanced surveillance initiated in 2003, identified human immunodeficiency virus (HIV)-infection and incomplete vaccination as contributing factors for Hib transmission. The total number of laboratory-confirmed cases of H. influenzae remained unchanged because non-type b disease was being increasingly reported to the surveillance system concomitant with system enhancements. Children with non-typable disease were more likely to be HIV-positive (32 of 34, 94%) than children with Hib disease (10 of 14, 71%), P = 0.051. Recent Hib isolates were more likely to be multidrug resistant (2% in 1999–2000 versus 19% in 2003–04, P = 0.001). Conclusion Data from a newly established national laboratory-based surveillance system showed a decrease in Hib disease burden among South African children following conjugate vaccine introduction and identified cases of non-typable disease associated with HIV infection. Bulletin of the World Health Organization 2006;84:811-818. Voir page 816 le résumé en français. En la página 816 figura un resumen en español. Introduction Use of conjugate vaccines for the prev vention of Haemophilus influenzae type b (Hib) disease in children has subv stantially decreased the burden of disease in developed 1–3 and developing countries .4–7 These vaccines are highly effective against invasive disease and may prevent up to 25% of radiographiv cally confirmed pneumonia,8–10 but are not used in some developing countries due to their high cost and because Hib remains undervrecognized as a cause of severe disease and death.11 The vaccinev preventable burden of Hib disease is likely to be greater among HIVvinfected than among uninfected children due to much higher rates of Hib disease.12 The vaccines have, however, been less effective in HIVvinfected children,13–14 highlighting the need for evaluation of the impact of vaccine introduction in a Respiratory and Meningeal Pathogens Research Unit (RMPRU), National Institute for Communicable Diseases of the National Health Laboratory Service, Private Bag X4, Sandringham 2131, Gauteng, South Africa. Correspondence to Dr von Gottberg (email: annev@nicd.ac.za). b Respiratory Diseases Branch, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA,USA. c Hubert Department of Global Health, Rollins School of Public Health and Division of Infectious Diseases, School of Medicine, Emory University, Atlanta, GA, USA. d Members of GERMS-SA (List of members on web version only, available from: http://www.who.int/bulletin). Ref. No. 06-030361 (Submitted: 24 January 2006 – Final revised version received: 28 April 2006 – Accepted: 5 May 2006) Impact of conjugate Haemophilus influenzae type b (Hib) vaccine introduction in South Africa A von Gottberg,a L de Gouveia,a SA Madhi,a M du Plessis,a V Quan,a K Soma,a R Huebner,a B Flannery,b A Schuchat,b KP Klugman,c & the Group for Enteric, Respiratory and Meningeal Disease Surveillance in South Africa (GERMS-SA) d .817 ةحفص في ةيبرعلاب صخللما لىع علاطلاا نكيم populations with a high burden of HIV infection. South Africa was the first country in Africa to selfvfinance and incorporate the Hib vaccine into its routine child immunization schedule from July 1999. It concurrently established a national laboratoryvbased surveillance for invasive Hib disease to document the impact of routine vaccination on Hib disease.15 We analysed data from this surveillance system for the first five years to document changes in the number of reported cases of laboratoryvconfirmed H. influenzae disease among children less than five years old in South Africa. Methods South Africa introduced the Hib vaccine (Tetramune, Wyeth Lederle Vaccines and Pediatrics) in March 1998 as part of a pneumococcal conjugate vaccine trial in Soweto (urban black community with 120 000 children less than five years old in 1995), Gauteng province, affecting a total of 19 267 children.14 Populationv based studies in South Africa had previv ously demonstrated rates of invasive Hib disease of 170 per 100 000 infants below one year of age.14,16 National populav tion estimates for children less than five years old in 2002 were 4 455 000, and in Gauteng and Western Cape (from where majority of the disease is reported) 737 600 and 409 600, respectively. National laboratory-based surveillance system The surveillance system defined inv vasive H. influenzae and Streptococcus pneumoniae disease as isolation of the organisms from normally sterile body fluids of South Africans of all ages.15 All clinical laboratories in South Africa were 812 Bulletin of the World Health Organization | October 2006, 84 (10) Research Impact of Hib vaccine in South Africa A von Gottberg et al. requested to report cases of invasive H. influenzae infection and send isolates to the central reference laboratory at the Respiratory and Meningeal Pathov gens Research Unit, National Institute for Communicable Diseases (NICD) (branch of the National Health Laborav tory Service (NHLS)) in Johannesburg. We excluded isolates from the same disease episode. Clinical laboratories routinely culv ture specimens of blood and cerebrov spinal fluid for isolation of bacteria, alv though before this time, no nationwide system existed for reporting cases or collecting isolates. The number of cliniv cal laboratories reporting cases increased during each year of our study period — 80 laboratories during July 1999–June 2000 to 88, 91 and 103 in 2000–01, 2001–02 and 2002–03, respectively. We observed no deterioration in laboratory standards. The surveillance system was enhanced in 2003 by placing additional surveillance staff in 15 hospitals in seven of nine provinces, thereby increasing the number of reporting laboratories to 126 in 2003–04. From 2003, we reviewed cases at sentinel sites throughout the country for outcome, HIV status (based on serology for all ages and serology with clinical features and/or positive polymerase chain reaction (PCR) results for children less than 18 months old) and vaccination history. Laboratories were encouraged to report all cases of laboratoryvconfirmed disease even if no isolates were available. Annual regional laboratory audits identified 54 laborav toryvconfirmed cases of H. influenzae among all ages during the study period (24, 5, 12, 9 and 4 cases per 12vmonth interval) that were not reported to the NICD, suggesting that approximately 70% of all laboratoryvconfirmed H. influenzae infections were reported. We added the cases identified by audit to the surveillance database. Hib conjugate vaccine The vaccine was part of a combination product (CombActHIB, Aventis Pasteur) containing diphtheria toxoid, tetanus toxoid and whole cell pertussis antigen (DTwP) for children receiving their first dose of diphtheria–tetanus–pertussis vaccine. The vaccine was prepared by reconstituting dried Hib conjugate powv der with DTwP as diluent. The recomv mended dosage schedule was at six, 10 and 14 weeks without booster. There was no catchvup schedule for vaccinating children who had already received their first dose of DTwP. We experienced sporadic shortages of the combination vaccine from 1999 through 2002. Identification of isolates We identified isolates with the gvaminov laevulinic acid (ALA)vporphyrin test reaction and API NH (bioMérieux sa, Marcyvl’Etoile, France).17 Slide aggluv tination for serotyping was performed using agglutinating sera for types a–f (Murex Biotech Ltd, Dartford, Kent, England). Serotyping results for all isov lates were confirmed by PCR.18 Cases without isolates were excluded from further analysis. Susceptibility testing was performed according to Clinical and Laboratory Standards Institute guidev lines.19 Minimum inhibitory concenv trations were determined by Etest (AB Biodisk, Solna, Sweden) for isolates not susceptible (intermediately resistant and resistant) to any antibiotic. Nitrocefin was used to test for bvlactamase producv tion. Multiple drugvresistant isolates were isolates not susceptible to ampicilv lin, chloramphenicol and trimethoprimv sulfamethoxazole. Analyses The mean age of children less than five years old for each 12vmonth period was compared using the nonparametric Kruskal–Wallis test. Percentage decreases were calculated by comparing the number of reported cases in July 1999–June 2000 with cases reported in July 2003–June 2004. Rates of reported cases of invasive Hib disease were calculated for 12vmonth periods from 1 July to 30 June of the following year. Numerators were the number of viable H. influenzae isolates confirmed as serotype b at the reference laboratory. Denominators were midvyear population estimates obtained from the South African Health Information Sysv tems Programme. We obtained vaccine coverage data from the Department of Health 20 and Health Systems Trust,21 and HIV seroprevalence estimates from antenatal clinic surveys.22,23 We used c²vtest to analyse trends in the proporv tion of antimicrobial resistant isolates over the five periods and managed and analysed data using Epi Info software, version 6.04d.24 Findings In our study, 920 cases of invasive H. influenzae disease were reported to the surveillance system from July 1999 to June 2004 for all ages; 847 (92%) provided the patient’s age. Of the 920 isolates, 712 (77%) were recovered for serotyping and antimicrobial susv ceptibility testing. With the increased number of surveillance audits through the period, we identified an increasing number of laboratoryvconfirmed cases retrospectively for which no isolates were available. Cases with isolates therefore decreased from 84% during 1999–2000 to 74% during 2003–04, with a signifiv cant downward trend over the fivevyear period (P = 0.02). Of the 712 viable isolates, 300 (42%) were serotype b (109, 61, 43, 44 and 43, respectively, for the five periods), 104 (15%) were other capsular types and 308 (43%) were unencapsulated H. influenzae. Among cases for which the patient’s age was known, 218 (78%) of 279 Hib isolates and 225 (61%) of 370 other H. influenzae isolates were among children less than five years old (Table 1). Of Hib cases aged five years and above, 16 (6%) occurred among those aged 5–9 years, 5 (2%) among those aged 10–14 years and 40 (14%) among adults aged 15 years or more. We found that reported cases of invasive disease among children less than five years old caused by Hib decreased substantially during the fivevyear period, while those caused by H. influenzae other than Hib and S. pneumoniae increased to more than twofold (Table 1). Among children less than five years old with invasive Hib disease, 60% (130 cases) occurred among those below one year (Table 2), 13% (29) among those aged 12–17 months and 27% (59) among those aged 18 months or more. We noted no significant change in the median age (9 months) of Hib cases among children less than five years old (P = 0.162) durv ing the entire study period. We found positive cultures from cerebrospinal fluid specimens (with or without other speciv mens) for over half of these cases (113, 52%), from blood specimens for 104, and from a pleural fluid specimen for one case. We found no reported cases of epiglottitis. Our analyses revealed that Hib cases decreased by 65% among children less than one year old (55 cases in 1999– 2000 to 19 in 2003–04) (Table 3). In Gauteng, Hib cases decreased from 20 to 10, and in the Western Cape from 12 to 2, during the same time period. In Gauteng and Western Cape, rates of reported Hib disease among children below one year decreased by 57% (13.1 813Bulletin of the World Health Organization | October 2006, 84 (10) Research A von Gottberg et al. Impact of Hib vaccine in South Africa cases per 100 000 in 1999–2000 versus 5.7 per 100 000 in 2003–04; 95% confidence interval (CI): 8–80%, P = 0.04), and 85% (14.6 versus 2.2 cases per 100 000; 95% CI: 32–97%, P = 0.010), respectively (Table 3). We also found a 79% decrease (from 34 to 7 cases) in national recording of inv vasive disease among children 1–4 years of age (Table 3). The decrease in this age group was also evident in Gauteng and Western Cape (13 to 5 cases and 16 to 1 case, respectively). Our analyses of anv tenatal HIV seroprevalence rates among pregnant women showed that rates durv ing 2000–04 increased in Gauteng (from 29% to 33%) and Western Cape (from 9% to 15%) (Table 3). We found that all ampicillinvresistant Hib isolates produced bvlactamase. Alv though the number of Hib cases dev creased during the final surveillance year, isolates of Hib were more likely to be amv picillin resistant (8 (31%) of 26 cases in Table 1. Reported cases of invasive disease caused by Haemophilus influenzae and Streptococcus pneumoniae in South African children less than five years old, by 12-month period Disease Years of surveillance 1999–2000 2000–01 2001–02 2002–03 2003–04 % changea n (%) Haemophilus influenzae Type b 89 (65) 43 (46) 27 (30) 33 (31) 26 (17) -71 Other typable b 8 (6) 6 (6) 11 (12) 13 (12) 25 (16) 213 Nontypable 18 (13) 19 (20) 32 (35) 35 (33) 58 (37) 217 No isolate available 22 (16) 26 (28) 21 (23) 25 (24) 46 (30) Not applicable All 137 94 91 106 155 12 Streptococcus pneumoniae (all serotypes) 453 691 788 733 1218 169 a Comparing 1999–2000 with 2003–04. b Includes serotypes a (n = 10), c (n = 6), d (n = 5), e (n = 3) and f (n = 39). Table 2. Reported Haemophilus influenzae serotype b (Hib) disease among South African children less than five years old, by age group and 12-month period Age group Years of surveillance 1999–2000 2000–01 2001–02 2002–03 2003–04 Reported Hib casesa (all age groups) 89 43 27 33 26 <6 weeks 2 2 1 2 3 6 weeks to <1 year 53 24 14 13 16 >14 weeksb to <1 year 43 20 13 10 14 1 to <2 years 21 8 6 4 5 2 to <3 years 9 9 4 4 0 3 to <4 years 2 0 2 5 2 4 to <5 years 2 0 0 5 0 a Excludes 21 cases reported without exact age specified: 4, 6, 6, 2 and 3, respectively by 12-month period. b Vaccination schedule for three doses of Hib conjugate vaccine: 6, 10 and 14 weeks of age. 2003–04 versus 14 (16%) of 89 isolates in 1999–2000; P = 0.036, c²vtest for trend) (Fig. 1). In addition, even though the absolute number of cases decreased over the years, the proportion of multiple drugvresistant isolates increased by 2%, 7%, 15%, 15% and 19% for each 12v month period respectively (P = 0.001, c²vtest for trend). Before the introduction of the Hib conjugate vaccine, a national survey of vaccination coverage in 1998 estimated that 72% of infants had received three doses of DTwP by one year of age.20,21 Annual coverage figures based on routine clinic reports of vaccinations estimated that 64% of South African children were fully immunized (three doses of DTwP and Hib) by one year of age in 2000, 72% in 2001 and 68% in 2002. Provincial estimates for Gauteng were lower for 2002 at 61%, but similar to the national estimates for the other two years. In Western Cape 79%, 73% and 56% were immunized in 2000, 2001 and 2002, respectively. During the 18 months of enhanced surveillance (January 2003–June 2004), 212 H. influenzae cases were reported nationally among children less than five years old (44/154 (28%) of these confirmed cases of Hib); 114 (54%) at sentinel hospitals (18/82 Hib (22%), 46 nontypable, 18 other than serotype b cases, and 32 cases with no viable isov lates). Vaccination status was available for 15 Hib cases, four of whom were too young to be immunized, one fivev monthvold child was unimmunized and 10 received at least one dose of Hib vaccine. A ninevmonthvold HIVv uninfected child who had received a third dose of the Hib conjugate vaccine four months before presenting with Hib meningitis, subsequently died. HIV status was documented for 15 cases: 11 (73%) were HIVvinfected, including five of eight cases less than one year of age. 814 Bulletin of the World Health Organization | October 2006, 84 (10) Research Impact of Hib vaccine in South Africa A von Gottberg et al. Table 3. Number and rates of reported cases of invasive Haemophilus influenzae serotype b disease in children less than five years old in Gauteng and Western Cape provinces and South Africa as a whole, by 12-month period Region and age group Years of surveillance 1999–2000 2000–01 2001–02 2002–03 2003–04 Total South Africa <1 year (cases/100 000) 55 (6.2) 26 (2.9) 15 (1.7) 15 (1.6) 19 (2) 130 1–4 years (cases/100 000) 34 (0.9) 17 (0.5) 12 (0.3) 18 (0.5) 7 (0.2) 88 HIV a seroprevalence rates (%) in antenatal clinic attendees 24.5 24.8 26.5 27.9 29.5 Number of laboratories reporting nationally 80 88 91 103 126 Gauteng Province <1 year (cases/100 000) 20 (13.1) 11 (7.0) 5 (3.1) 8 (4.7) 10 (5.7) 54 1–4 years (cases/100 000) 13 (2.4) 9 (1.6) 6 (1.1) 11 (1.9) 5 (0.9) 44 HIV seroprevalence rates (%) in antenatal clinic attendees 29.4 29.8 31.6 29.6 33.1 Western Cape Province <1 year (cases/100 000) 12 (14.6) 6 (7.1) 5 (5.8) 2 (2.3) 2 (2.2) 27 1–4 years (cases/100 000) 16 (5.1) 4 (1.3) 5 (1.6) 3 (0.9) 1 (0.3) 29 HIV seroprevalence rates (%) in antenatal clinic attendees 8.7 8.6 12.4 13.1 15.4 a HIV = human immunodeficiency virus. Among four cases who had received one or more Hib vaccine dose and were of known HIVvstatus, three (75%) were HIVvinfected. Clinical outcomes were reported for 29 cases since January 2003, five (17%) of whom died. We observed that nationally over the five years, the median age for nontypable disease (n = 162) and disease due to serotypes other than serotype b (n = 63) among children less than five years old did not change (median age 10 months for both groups). During the period of enhanced surveillance, children with nontypable disease were more likely to be HIVvpositive (32 of 34, 94%) than those with Hib disease (10 of 14, 71%), P = 0.051. All children who had serov types other than b (12 of 12) were HIV positive. Discussion In South Africa, a national laboratoryv based surveillance for invasive Hib disv ease demonstrated a significant decrease in cases of invasive disease following the introduction of Hib conjugate vaccine into the routine child immunization schedule. While surveillance data did not provide an accurate estimate of the true burden of Hib disease due to limitations of the reporting system, the demonstration of vaccine impact at the national level is important given the decision to provide this relatively expensive vaccine for all South African children. The cost benefits of administerv ing this vaccine to a 1992 Cape Town birth cohort (n = 46 537) was between US$ 0.8 million and US$ 1.2 million.25 Our findings are especially important given the high prevalence of HIV in the country. Although the laboratory reporting system in South Africa may underesv timate the incidence of Hib disease among children less than five years old, we believe the decrease in Hib disease is a minimum estimate of the full impact of the vaccine in South Africa. Populav tionvbased studies conducted in Soweto (Gauteng province) in 1997–98 and Cape Town (Western Cape province) in 1991–92 (before the introduction of Hib vaccine) identified annual incidences of invasive Hib disease of approximately 170 cases per 100 000 children below one year.14,16 These rates were much higher than those detected by our surv veillance in these two provinces during July 1999–June 2000 — 13.1 and 14.6 cases per 100 000 children below one year. In Gauteng, the vaccine had been administered to Soweto children since 1998, and since our surveillance system was established at the time of vaccine introduction (i.e. July 1999) the initial rates of Hib disease are likely to reflect some impact of the immunization. Morev over, the previmmunization studies were performed at academic hospitals where specimens are routinely collected for diagnostic purposes and laboratories are wellvequipped. We have seen improvev ments in case ascertainment throughout the country reflected in the increase in isolates of nontype b H. influenzae and S. pneumoniae. In addition, shortages of vaccine were reported during the first years. Thus, we believe that data from the national surveillance are likely to underestimate the impact of Hib vacv cine and that the 65% decrease in cases among children below one year during the study period should be interpreted as a minimum estimate.3,26 In South Africa, national estimates suggest that 8% of 1.1 million children born in 2002 were infected with HIV at birth or through breastfeeding durv ing their first year of life.27 Our analysis revealed that the decrease in Hib disease was lower in Gauteng, where HIV serov prevalence rates were more than twice that in Western Cape. HIV infection was very common among Hib cases at sentinel sites. Lower vaccine effectivev ness and increased susceptibility to Hib disease among HIVvinfected children may contribute to the persistent low rates of Hib disease in South Africa.13,14 Further studies are needed to deterv mine the relative importance of these two factors. With antiretroviral therapy decreasing mortality and progression to AIDS among infants,28 and its implev mentation in Africa showing promising 815Bulletin of the World Health Organization | October 2006, 84 (10) Research A von Gottberg et al. Impact of Hib vaccine in South Africa results,28,29 it will become more common in paediatric care in South Africa.30 Thus, monitoring of Hib disease may influence decisions to include additional doses of Hib and other vaccines for HIVvinfected children.31 We observed an increase in reported cases of nonvHib disease possibly due to improved quality of surveillance, which is supported by the increase in reported pneumococcal disease over the same time period. These diseases may howv ever also be increasing due to increases in the number of persons living with HIV infection. Data from a small numv ber of cases from sentinel sites showed that HIV infection was more common among paediatric cases of H. influenzae due to nontypable strains than among cases of Hib. Another explanation may be replacement disease, although it has not been significant in other parts of the world,32,33 HIVvcoinfection may conv tribute to other strains filling the niche previously occupied by Hib. Our data do not allow us to distinguish between the relative contributions of these factors to the observed increase. The reported coverage with the three doses of Hib vaccine in South Africa was less than that described in developed countries,26,34 although several limitations with regard to both numerav tor data and population denominators hamper accurate coverage estimates.20,21 We were unable to obtain sufficient data to determine the true incidence of vaccine failures. Failure after complete vaccination among children 14 weeks old or above was recorded for only one child. We believe that obtaining betv ter data on vaccination histories will be necessary to determine the role of vaccine failure among infants presentv ing with Hib disease.35–37 South Africa uses an accelerated schedule for Hib vaccine at six, 10 and 14 weeks without a booster dose,15 which might increase disease prevalence among older children due to waning immunity.35,38 In the last year of surveillance (2003–04) however, only seven of 26 cases of Hib disease (for whom age was recorded) occurred after the age at which a booster may be given (i.e. children more than one year old). We believe that the use of national surveillance data has several important limitations. The true burden of potenv tially preventable Hib disease may be significantly higher than that observed by culturevconfirmed disease alone.8–11 We included calculated rates of Hib disv ease only for cases where viable isolates could be confirmed as type b and for which the age of the patient was known. We did not adjust for the increase in the number of reporting laboratories, or the impact of enhancements made to the surveillance system in 2003, both of which likely increased the number of Hib cases identified. The low number of cases from many provinces may be due to several factors, including low acv cessibility to health care in rural areas, reduced numbers of blood cultures being taken per patients admitted,39 smaller rural laboratories not having resources for diagnosis unless as part of studies 40 and underreporting of diagnosed cases by the laboratory to the surveillance unit. Although laboratoryvconfirmed Hib cases are notifiable to the Department of Health in South Africa since 1999, notification remains uncommon and no cases were identified through the national reporting system during our fivevyear study period. Conclusion The inclusion of the Hib conjugate vacv cine in the child immunization schedv ule is justified in the face of the HIV epidemic which affects a large number of newborns. Increasing antibiotic resisv tance among Hib isolates in our popuv lation12,41 is an additional justification for vaccine introduction. In the future, better information about underlying conditions and vaccine status together with a carefully planned casevcontrol study will assist decisionvmakers and public health experts in understanding the possible reasons for the transmisv sion of Hib disease among children in South Africa. This may be especially important with the increasing survival of young children with HIVvinfections due to the recent introduction of comv prehensive care including antiretroviral therapy. O Acknowledgements We thank all laboratory and clinical staff throughout South Africa for contributv ing to national surveillance. Funding: The United Nations Children’s Fund (UNICEF) provided startvup fundv ing in 1999. This publication was supv ported in part by a cooperative agreement (number U60/CCU022088) from the Centers for Disease Control and Prevenv tion (CDC), Atlanta, Georgia, and the United States Agency for International Development’s Antimicrobial Resistance Initiative. (The contents are solely the responsibility of the authors and do not necessarily represent the official views of the CDC.) Competing interests: none declared. Fig. 1. Proportion of non-susceptible isolates causing Haemophilus influenzae serotype b disease in children below five years, by category for each of the 12-month periods, South Africa 2003–04 (n = 26) 2001–02 (n = 27) 2000–01 (n = 43) Pe rc en ta ge 50 0 1999–2000 (n = 89) Ampicillina Chloramphenicolb Trimethoprim-sulfamethoxazolec Multiple drug resistance 2002–03 (n = 33) 45 40 35 30 25 20 15 10 5 a c² - test for trend, P = 0.04. b P = 0.001. c P = 0.06. 816 Bulletin of the World Health Organization | October 2006, 84 (10) Research Impact of Hib vaccine in South Africa A von Gottberg et al. Résumé Effet de l’introduction du vaccin conjugué anti-Haemophilus influenzae type b (Hib) en Afrique du Sud Objectif Analyser les tendances observées dans les infections invasives à Haemophilus influenzae en Afrique du Sud pendant les cinq premières années suivant l’introduction du vaccin conjugué anti-Haemophilus influenzae type b (Hib) dans le calendrier de vaccination systématique de l’enfant. Méthodes On a utilisé les données de la surveillance nationale au laboratoire pour définir les cas d’infection invasive à H. influenzae entre juillet 1999 et juin 2004 et soumis des isolements au sérotypage et à des épreuves de sensibilité aux antimicrobiens. Résultats Le nombre absolu de cas d’infection à Hib (notifiés au système de surveillance national) chez l’enfant de moins d’un an a diminué de 65 %, passant de 55 en 1999-2000 à 19 en 2003-2004. Le renforcement de la surveillance commencé en 2003 a permis de constater que l’infection par le virus de l’immunodéficience humaine (VIH) et la vaccination incomplète constituaient des facteurs contribuant à la transmission du Hib. Le nombre total de cas d’infection à H. influenzae confirmés au laboratoire est resté inchangé, les infections n’appartenant pas au type b étant de plus en plus notifiées au système de surveillance à mesure que celui-ci devenait plus performant. Les enfants touchés par une infection à Haemophilus de type impossible à déterminer étaient plus souvent VIH-positifs (32 sur 34, 94 %) que les enfants infectés par Hib (10 sur 14, 71 %, p = 0,051). On a également observé une probabilité plus grande de multirésistance dans les isolements récents de Hib (2 % en 1999-2000 contre 19 % en 2003-2004, p = 0,001). Conclusion Les données issues d’un système national de surveillance au laboratoire récemment mis en place ont fait apparaître une diminution de la charge de morbidité due à Hib chez les enfants sud-africains à la suite de l’introduction du vaccin conjugué et permis d’identifier des infections à Haemophilus dont le type était impossible à déterminer, associées à l’infection par le VIH. Resumen Repercusión de la introducción de la vacuna conjugada contra Haemophilus influenzae tipo b (Hib) en Sudáfrica Objetivo Analizar las tendencias de los casos notificados de enfermedad invasiva por Haemophilus influenzae en Sudáfrica durante los cinco primeros años de utilización de la vacuna conjugada contra Haemophilus influenzae tipo b (anti-Hib) en el calendario de vacunación infantil sistemática. Métodos Usamos los datos de vigilancia obtenidos por el laboratorio nacional para identificar los casos de enfermedad invasiva por H. influenzae registrados entre julio de 1999 y junio de 2004, así como las cepas aisladas enviadas para serotipificación y análisis de la sensibilidad a los antimicrobianos. Resultados La cifra absoluta de casos de infección por Hib (notificados al sistema de vigilancia nacional) entre los niños menores de un año se redujo en un 65%, de 55 casos en 1999- 2000 a 19 casos en 2003-2004. La vigilancia mejorada iniciada en 2003 identificó la infección por el virus de la inmunodeficiencia humana (VIH) y la vacunación incompleta como factores contribuyentes a la transmisión de Hib. El número total de casos de infección por H. influenzae confirmados en laboratorio se mantuvo inalterado debido a que la enfermedad de tipo no b se notificó con creciente frecuencia al sistema de vigilancia como consecuencia de la mejora del sistema. Los niños con enfermedad no tipificable tenían más probabilidades de ser VIH-positivos (32 de 34; 94%) que los niños con enfermedad por Hib (10 de 14; 71%), P = 0,051, y los aislados recientes de Hib tenían más probabilidades de ser multirresistentes (2% en 1999-2000, frente al 19% de 2003-2004, P = 0,001). Conclusiones Los datos de un nuevo sistema nacional de vigilancia basado en el laboratorio mostraron una disminución de la carga de morbilidad por Hib entre los niños sudafricanos tras la introducción de vacunas conjugadas e identificaron casos de enfermedad no tipificable asociada a la infección por VIH. 817Bulletin of the World Health Organization | October 2006, 84 (10) Research A von Gottberg et al. Impact of Hib vaccine in South Africa صخلم ايقيرفأ بونج في ةيلزـنلا تايمدتسملل ئيابلا طمنلل نرـتقلما حاقللا جاتنإ يرثأت يتلا ةيلزـنلا تايمدتسلما نع ةمجانلا ضارملأا تاهاجتا ليلحت :فدهلا لاخدإ نم لىولأا سمخلا تاونسلا نمض ايقيرفأ بونج في اهثودح نع غلبأ ةينيتورلا ةطخلا نمض ةيلزـنلا تايمدتسملل ئيابلا طمنلل نرـتقلما حاقللا .لافطلأا عينمتل ديعصلا لىع تابرتخلما لىع زكترلما دصرـتلا تايطعم انمدختسا :ةقيرطلا ةيلزـنلا تايمدتسلما نع ةمجانلا ضارملأا تلااح لىع فرعتلل ينطولا انيرجأو ،2004 وينوي/ناريزحو 1999 ويلوي/زوتم ينب ةرـتفلا في ةيزاغلا ةباجتسلاا تارابتخاو )ةيلصلما طانملأا لىع فرعتلا تارابتخا( ًايلصم ًاطيمنت .تابوركلما تاداضلم نم ئيابلا طمنلا نع ةمجانلا تلااحلل قلطلما ددعلا صقن دقل :تادوجولما لافطلأا ينب ينطولا دصرـتلا ماظن في اهنع غلبأ يتلاو ةيلزـنلا تايمدتسلما ةلاح 19 تغلبف ،%65 رادقبم رمعلا نم ةدحاو ةنس نع مهرماعأ لقت نيذلا .2000 – 1999 ةترفلا في ةلاح 55 تناك نأ دعب 2004 – 2003 ةرـتفلا في زديلإا سويرفب ىودعلا نأ 2003 ماع ئشنأ يذلا زّزعلما دصرـتلا فشك دقو نم ئيابلا طمنلا ةياسر في ةمهاسلما لماوعلا نم ماه لمكتسلما يرغ ميعطتلاو ةد َّكؤلما تلااحلا نم ليماجلإا ددعلا نع غلابلإا يرغتي لمو .ةيلزـنلا تايمدتسلما ضارملأا نع غلابلإا نلأ ًارظن ،ةيلزـنلا تايمدتسلما نع ةمجانلاو ًايبرتخم نمض رمتسم ديازـت في ةيلزـنلا ةيمدتسلما نم ةيئابلا يرغ طانملأا نع ةمجانلا نكي لم نيذلا لافطلأا امأ .ماظنلا اذه زيزعت ببسب كلذو ،دصرـتلا ماظن مهيدلف مهيدل ضرملل ةببسلما ةيلزـنلا تايمدتسلما طنم لىع فرعتلا ناكملإاب ًلافط 32 مهددع غلبو ،زديلإا سويرفل ينـيباجيإ اونوكي نلأ بركأ لماتحا لافطلأا ىدل لماتحلاا نم بركأ اذهو ،%94 لداعي اذهو ،ًلافط 34 ينب نم غلبو( ةيلزـنلا تايمدتسلما نم ئيابلا طمنلا نع مجانلا ضرلماب ينباصلما لماتحا ةميقو ،%61 لداعي اذهو ،ًلافط 14 ينب نم لافطأ 10 مهددع تايمدتسلما نم ئيابلا طمنلا نم ةثيدحلا تادرفتسلما تناك دقو .)0.05 في %2 تناك دقف ،ةددعتم ةيودلأ ةمواقم نوكت نلأ ًلاماتحا ثركأ ةيلزـنلا ةميقو ،2004 – 2003 ةترفلا في %19 تحبصأو 2000 – 1999 ةرـتفلا .0.001 لماتحا لىع زكترلما دصرـتلل ًاثيدح ئشنأ ماظن في تايطعلما رهظت :جاتنتسلاا طمنلا نع ةمجانلا ضارملأا ءبع في ًاصقانت ينطولا ديعصلا لىع تابرتخلما حاقللا لاخدإ ولت ايقيرفأ بونج في لافطلأا ينب ةيلزـنلا تايمدتسلما نم ئيابلا فرعتلا نكيم لا يتلا تايمدتسلما نع ةمجانلا تلااحلا لىع فرعتلاو نرـتقلما .زديلإا سويرفب ىودعلل ةقفارلماو اهطانمأ لىع References 1. Adams WG, Deaver KA, Cochi SL, Plikaytis BD, Zell ER, Broome CV, et al. Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era. JAMA 1993;269:264-6. 2. Heath PT, McVernon J. The UK Hib vaccine experience. Arch Dis Child 2002;86:396-9. 3. Peltola H. Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin Microbiol Rev 2000;13:302-17. 4. Wenger JD, DiFabio J, Landaverde JM, Levine OS, Gaafar T. Introduction of Hib conjugate vaccines in the non-industrialized world: experience in four ‘newly adopting’ countries. Vaccine 1999;18:736-42. 5. Wilson N, Mansoor O, Wenger J, Martin R, Zanardi L, O’Leary M, et al. Estimating the Haemophilus influenzae type b (Hib) disease burden and the impact of Hib vaccine in Fiji. Vaccine 2003;21:1907-12. 6. Martin M, Casellas JM, Madhi SA, Urquhart TJ, Delport SD, Ferrero F, et al. Impact of Haemophilus influenzae type b conjugate vaccine in South Africa and Argentina. Pediatr Infect Dis J 2004;23:842-7. 7. Adegbola RA, Secka O, Lahai G, Lloyd-Evans N, Njie A, Usen S, et al. Elimination of Haemophilus influenzae type b (Hib) disease from The Gambia after the introduction of routine immunisation with a Hib conjugate vaccine: a prospective study. Lancet 2005;366:144-50. 8. Mulholland K, Hilton S, Adegbola R, Usen S, Oparaugo A, Omosigho C, et al. Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate vaccine [corrected] for prevention of pneumonia and meningitis in Gambian infants. Lancet 1997;349:1191-7. 9. Levine OS, Lagos R, Munoz A, Villaroel J, Alvarez AM, Abrego P, et al. Defining the burden of pneumonia in children preventable by vaccination against Haemophilus influenzae type b. Pediatr Infect Dis J 1999;18:1060-4. 10. de Andrade AL, de Andrade JG, Martelli CM, Silva SA, de Oliveira RM, Costa MS, et al. Effectiveness of Haemophilus influenzae b conjugate vaccine on childhood pneumonia: a case-control study in Brazil. Int J Epidemiol 2004;33:173-81. 11. Peltola H. Burden of meningitis and other severe bacterial infections of children in Africa: implications for prevention. Clin Infect Dis 2001;32:64-75. 12. Madhi SA, Petersen K, Madhi A, Khoosal M, Klugman KP. Increased disease burden and antibiotic resistance of bacteria causing severe community- acquired lower respiratory tract infections in human immunodeficiency virus type 1-infected children. Clin Infect Dis 2000;31:170-6. 13. Madhi SA, Kuwanda L, Saarinen L, Cutland C, Mothupi R, Kayhty H, et al. Immunogenicity and effectiveness of Haemophilus influenzae type b conjugate vaccine in HIV infected and uninfected African children. Vaccine 2005;23:5517-25. 14. Madhi SA, Petersen K, Khoosal M, Huebner RE, Mbelle N, Mothupi R, et al. Reduced effectiveness of Haemophilus influenzae type b conjugate vaccine in children with a high prevalence of human immunodeficiency virus type 1 infection. Pediatr Infect Dis J 2002;21:315-21. 15. Huebner RE, Klugman KP, Matai U, Eggers R, Hussey G. Laboratory surveillance for Haemophilus influenzae type B meningococcal, and pneumococcal disease. Haemophilus Surveillance Working Group [Letter]. S Afr Med J 1999;89:924-5. 16. Hussey G, Hitchcock J, Schaaf H, Coetzee G, Hanslo D, van Schalkwyk E, et al. Epidemiology of invasive Haemophilus influenzae infections in Cape Town, South Africa. Ann Trop Paediatr 1994;14:97-103. 17. Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Yolken RH, (editors). Manual of Clinical Microbiology. 8 ed. Washington DC: ASM Press; 2003. 18. Falla TJ, Crook DW, Brophy LN, Maskell D, Kroll JS, Moxon ER. PCR for capsular typing of Haemophilus influenzae. J Clin Microbiol 1994;32:2382-6. 19. National Committee for Clinical Laboratory Standards (NCCLS). Performance standards for antimicrobial disk susceptibility testing. Fourteenth informational supplement. 2004. NCCLS: Wayne, Pennsylvania. NCCLS document M100-S14. 20. Department of Health. South Africa Demographic and Health Survey — 1998. Available from: http://www.doh.gov.za/facts/index.html 21. Health Systems Trust. Immunisation coverage in children <1 year. Available from: http://new.hst.org.za/indic/indic.php/107/?mode=data 22. Department of Health. National HIV and syphilis antenatal sero-prevalence survey in South Africa 2001. Available from: http://www.doh.gov.za/aids/ docs/sum-report.html 23. Department of Health. National HIV and syphilis antenatal sero-prevalence survey in South Africa 2004. Available from: http://www.doh.gov.za/docs/ reports/2004/hiv-syphilis.pdf 24. Dean AD, Dean JA, Burton JH, Dicker RC. et al. Epi Infor, version 6.04: a word processing, database, and statistics program for epidemiology on microcomputers. Atlanta: Centers for Disease Control and Prevention; 1996. 818 Bulletin of the World Health Organization | October 2006, 84 (10) Research Impact of Hib vaccine in South Africa A von Gottberg et al. 25. Hussey GD, Lasser ML, Reekie WD. The costs and benefits of a vaccination programme for Haemophilus influenzae type B disease. S Afr Med J 1995; 85:20-5. 26. Booy R, Heath PT, Slack MP, Begg N, Moxon ER. Vaccine failures after primary immunisation with Haemophilus influenzae type-b conjugate vaccine without booster. Lancet 1997;349:1197-202. 27. Dorrington RE, Bradshaw D, Budlender D. HIV/AIDS profile of the provinces of South Africa — indicators for 2002. Centre for Actuarial Research, Medical Research Council and the Actuarial Society of South Africa; 2002. 28. Foster C, Lyall EG. Children with HIV: improved mortality and morbidity with combination antiretroviral therapy. Curr Opin Infect Dis 2005;18:253-9. 29. Fassinou P, Elenga N, Rouet F, Laguide R, Kouakoussui KA, Timite M, et al. Highly active antiretroviral therapies among HIV-1-infected children in Abidjan, Cote d’Ivoire. AIDS 2004;18:1905-13. 30. Neal LJ, Yoganathan K, Roux P. HIV treatment in South African children. Lancet 2004;364:26. 31. Melvin AJ, Mohan KM. Response to immunization with measles, tetanus, and Haemophilus influenzae type b vaccines in children who have human immunodeficiency virus type 1 infection and are treated with highly active antiretroviral therapy. Pediatrics 2003;111:e641-4. 32. Ward JI. Invasive infections due to Haemophilus influenzae serotype f (Hif) — is Hif an emerging pathogen? Clin Infect Dis 1996;22:1077-8. 33. Ribeiro GS, Reis JN, Cordeiro SM, Lima JB, Gouveia EL, Petersen M, et al. Prevention of Haemophilus influenzae type b (Hib) meningitis and emergence of serotype replacement with type a strains after introduction of Hib immunization in Brazil. J Infect Dis 2003;187:109-16. 34. Bisgard KM, Kao A, Leake J, Strebel PM, Perkins BA, Wharton M. Haemophilus influenzae invasive disease in the United States, 1994-1995: near disappearance of a child vaccine preventable disease. Emerg Infect Dis 1998; 4:229-37. 35. Ramsay ME, McVernon J, Andrews NJ, Heath PT, Slack MP. Estimating Haemophilus influenzae type b vaccine effectiveness in England and Wales by use of the screening method. J Infect Dis 2003;188:481-5. 36. McVernon J, Trotter CL, Slack MP, Ramsay ME. Trends in Haemophilus influenzae type b infections in adults in England and Wales: surveillance study. BMJ 2004;329:655-8. 37. McVernon J, Andrews N, Slack MP, Ramsay ME. Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis. Lancet 2003;361:1521-3. 38. Garner D, Weston V. Effectiveness of vaccination for Haemophilus influenzae type b. Lancet 2003;361:395-6. 39. Quan V, Soma K, von Gottberg A, de Gouveia L, Schuchat A, Madhi SA, et al. Surveillance of invasive Streptococcus pneumoniae disease in South Africa in 2003. Programme and Abstracts, 4th International Symposium on Pneumococci and Pneumococcal Diseases, May 9–13, Helsinki, Finland. 2004. 40. Berkley JA, Lowe BS, Mwangi I, Williams T, Bauni E, Mwarumba S, et al. Bacteremia among children admitted to a rural hospital in Kenya. N Engl J Med 2005;352:39-47. 41. Hussey G, Hitchcock J, Hanslo D, Coetzee G, van Schalkwyk E, Pitout J, et al. Serotypes and antimicrobial susceptibility of Haemophilus influenzae. J Antimicrob Chemother 1994;34:1031-6.